|
View this as a webpage
Minnesota Department of Health
May 25, 2022
On May 20, the Centers for Disease Control and Prevention (CDC) updated their Interim Clinical Considerations for Use of COVID-19 Vaccines regarding:
- New guidance for booster dose in children ages 5–11 years.
- Updated guidance on second COVID-19 booster doses.
- Updated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-depleting therapies.
- Clarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A).
- Updated guidance for primary series vaccination after SARS-CoV-2 infection.
MDH’s Interim COVID-19 Vaccine Provider Guide, Template: COVID-19 Screening and Agreement and Pfizer-BioNTech COVID-19 Vaccine Protocol for 5-11 years has been updated to reflect the latest recommendations. Find these resources at COVID-19 Vaccine Providers.
On May 23, the Food and Drug Administration (FDA) revised upcoming VRBPAC meeting dates. The new dates are as follows:
-
June 14: Discussion on Moderna’s emergency use authorizations (EUA) request for 6 years through 17 years of age.
-
June 15: Discussion for Moderna’s EUA request for 6 months through 5 years and Pfizer-BioNTech EUA request for 6 months through 4 years of age, based on completion of EUA submission.
This revision was due to receiving new data from sponsors and expected submissions of EUA. Additional information can be found in the initial FDA News Release: FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines.
|
